Exact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.94), $0.11 better than the analyst estimate of ($1.05). Revenue for the quarter came in at $522 million versus the consensus estimate of $497.18 million.

GUIDANCE:

Exact Sciences sees Q3 2022 revenue of $1.98-2.022 billion, versus the consensus of $2.02 billion.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.